Drug-Induced Reactivation of VZV and HSV1-2 in Adult Patients with Multiple Sclerosis Receiving Disease-modifying Therapies: A Systematic Review and Meta-analysis - PubMed
19 hours ago
- #Multiple Sclerosis
- #Disease-Modifying Therapies
- #Herpesvirus Reactivation
- Drug-induced reactivation of VZV and HSV1-2 is a risk for adult MS patients on DMTs.
- This systematic review and meta-analysis compiled data from 78 studies (1996-2024).
- Alemtuzumab showed the highest reactivation rates: 6.28 for HSV and 4.89 for VZV per 100 persons over ~40 months.
- Fingolimod had lower rates: 1.77 for HSV and 0.55 for VZV per 100 persons over ~28-29 months.
- Natalizumab and rituximab had VZV reactivation rates of 0.29 and 1.19 per 100 person-years, respectively.
- Placebo arms showed HSV at 1.10 and VZV at 0.50 per 100 persons over ~45-49 months.
- The findings aim to support clinical strategies for screening, monitoring, and vaccination in MS patients on DMTs.